Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Image courtesy of Shutterstock

The University of Oxford has signed a collaboration agreement with Oxford University Hospitals NHS Foundation Trust and leading genetic analysis company Genomics plc to carry out a research project focused on the translation of whole genome sequencing into clinical practice.

The project, which is supported by the Wellcome Trust and Department of Health through the Health Innovation Challenge Fund, aims to establish genome sequencing – reading the entire DNA of a person – as a clinical tool across a wide range of disorders, including rare diseases and cancers. This will directly benefit the NHS in establishing new tools to improve healthcare. The study will also serve as a pilot for other large scale programmes to integrate genomics and healthcare. As part of the agreement, Genomics’ software will be applied to analyse and interpret up to 500 genome sequences focusing on rare diseases and cancer.

Read more

Similar stories

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Three NHSBT research units launch at University of Oxford

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford.